Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study

Valenzuela F.Korman N.J.Bissonnette R.Bakos N.TSEN-FANG TSAIHarper M.K.Ports W.C.Tan H.Tallman A.Valdez H.Gardner A.C.2020-10-222020-10-2220180007-0963https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052929660&doi=10.1111%2fbjd.16798&partnerID=40&md5=211fd2e495ded70bc8bf6dfe0551a97chttps://scholars.lib.ntu.edu.tw/handle/123456789/517557[SDGs]SDG3Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension studyjournal article10.1111/bjd.16798297826422-s2.0-85052929660